2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in patients with stage III-IV high-grade ovarian cancer.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Clovis Oncology, we spoke with Bradley J. Monk, MD, FACS, FACOG. Monk is a professor in the Division of Gynecologic Oncology at Arizona Oncology, part of the US Oncology Network, at the University of Arizona College of Medicine. He is also a professor at Creighton University School of Medicine at St. Joseph’s Hospital; the medical director of the US Oncology Research Network – Gynecologic Program; the vice-president and a member of the board of directors of the GOG-Foundation; and the co-director of GOG-Partners.
In our exclusive interview, Monk discussed pertinent efficacy and safety data from the phase 3 ATHENA-MONO trial (NCT03522246) that were presented at the 2022 ASCO Annual Meeting. This trial evaluated first-line maintenance treatment with rucaparib (Rubraca), a PARP inhibitor, in patients with stage III-IV high-grade ovarian cancer who were undergoing surgical cytoreduction and who had responded to first-line platinum-doublet chemotherapy. Rucaparib elicited a median progression-free survival of 28.7 months (95% CI, 23.0-not reached) vs 11.3 months (95% CI, 9.1-22.1) with placebo.
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Clovis Oncology. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.